CCR3 inhibition for ocular angiogenesis and macular...

Details CCR3 inhibition for ocular angiogenesis and macular... CCR3 inhibition for ocular angiogenesis and macular...

2011-08-30

2011-08-30

Epps-Smith, Janet L (Department: 1633)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

C424S139100

Reexamination Certificate

active

08008092

ABSTRACT:
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.

REFERENCES:
patent: 6207155 (2001-03-01), Grimaldi et al.
patent: 6806061 (2004-10-01), Gerard et al.
patent: 2002/0147312 (2002-10-01), O'Keefe et al.
patent: 2005/0069955 (2005-03-01), Plaksin et al.
patent: 2005/0191702 (2005-09-01), Mack et al.

Affiliated with

Also associated with

Rating

CCR3 inhibition for ocular angiogenesis and macular... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CCR3 inhibition for ocular angiogenesis and macular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR3 inhibition for ocular angiogenesis and macular... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2785159